Scientists want to be able to
clone early human embryos, using cells from patients with various diseases, so they can study the diseases in the lab and develop new treatments for them.
Not exact matches
Kass ably led the council members in a long debate on
cloning, with the result that
earlier this year they came out in opposition to
human cloning but divided on the use of
cloned embryos for research purposes.
The paper not only seemed to validate the group's claim a year
earlier that it had created a single cell line from a
cloned human embryo, but it also reported a huge increase in efficiency for the technique.
As
cloning pioneers Rudolf Jaenisch and Ian Wilmut have argued, «if
human cloning is attempted, those
embryos that do not die
early may live to become abnormal children and adults; both are troubling outcomes.»
Cloned early - stage
human embryos — and
human embryos generated only from eggs, in a process called parthenogenesis — now put therapeutic
cloning within reach
Rather than
clone humans, researchers take the
early stage
embryos that result from SCNT and then derive stem cells (pictured above, fluorescently tagged red).
ACT announced last November that they had
cloned early - stage
human embryos in a step toward therapeutic
cloning (which seeks to treat diseases by using genetic material from a patient's own cells) but the company believes that reproductive
cloning is too risky and unwarranted at this time.
A team of scientists from the New York Stem Cell Foundation Laboratory created 13
early - stage
human embryos that were partial genetic
clones of diabetic patients.